NTRK1 and malignant peripheral nerve sheath tumor: For example, a TPM3-NTRK1 fusion in an adolescent with a malignant peripheral nerve sheath tumour (MPNST) was identified, which is considered a very-high-priority actionable event, offering the patient a relevant treatment option (e.g. tropomyosin receptor kinase (TRK) inhibitor).